Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 345

Sort by

Sort Order Select

Journal Articles

Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML

Martin Wermke, Sabrina Kraus, Armin Ehninger, Ralf C. Bargou, Maria-Elisabeth Goebeler, Jan Moritz Middeke, Carla Kreissig, Malte von Bonin, Jan Koedam, Michael Pehl, Martin Bornhäuser, Hermann Einsele, Gerhard Ehninger, Marc Cartellieri

Blood (2021) 137 (22): 3145–3148.

https://doi.org/10.1182/blood.2020009759

Published: 2021

Journal Articles

Talazoparib Treatment Preferentially Depletes Cohesin-Mutant Clones in New In Vivo M odels of Cohesin-Mutant Myeloid Diseases

Mounica Vallurupalli, MD, Rebecca Gorelov, BS, Jacqueline S Garcia, MD, Elizabeth A Morgan, MD, Benjamin Ebert, MD, Zuzana Tothova, MD PhD

Blood (2019) 134 (Supplement_1): 560.

https://doi.org/10.1182/blood-2019-130308

Published: 2019

Journal Articles

Integrated Immune Signature Analyses Identifies Evolution of Distinct Immunoregulatory Cell Populations Which Control Alloreactivity after Allogeneic HSCT

James Aries, Sarah Charrot, Jennifer Ball, Matthew Mee, Symeon Theocharidis, Sofie Van Gassen, Sameena Iqbal, John G. Gribben, MD DSc, Jeff Davies, MBBS, PhD

Blood (2019) 134 (Supplement_1): 595.

https://doi.org/10.1182/blood-2019-124875

Published: 2019

Journal Articles

Pharmacological Inhibition of the RNA m 6 a Writer METTL3 As a Novel Therapeutic Strategy for Acute Myeloid Leukemia

Konstantinos Tzelepis, Etienne De Braekeleer, PhD MSc, Eliza Yankova, PhD, Justyna Rak, PhD, Demetrios Aspris, MSc, Ana Filipa Domingues, PhD, Richard Fosbeary, Alan Hendrick, PhD, Dan Leggate, PhD, Yaara Ofir-Rosenfeld, PhD, Alexandra Sapetschnig, PhD, Cristina Pina, MDDPhil, Mark Albertella, PhD, Wesley Blackaby, PhD, Oliver Rausch, PhD, George S. Vassiliou, FRCPath, MRCP, PhD, Tony Kouzarides, PhD

Blood (2019) 134 (Supplement_1): 403.

https://doi.org/10.1182/blood-2019-127962

Published: 2019

Journal Articles

Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor

Anthony R. Mato, MDMSCE, Ian W. Flinn, MD PhD, John M. Pagel, MD PhD DSc, Jennifer R. Brown, MD PhD, Chan Y. Cheah, Catherine C. Coombs, MD, Manish R. Patel, MD, S. Michael Rothenberg, MD PhD, Donald E. Tsai, MD PhD, Nora C. Ku, MD, Michael L. Wang, MD

Blood (2019) 134 (Supplement_1): 501.

https://doi.org/10.1182/blood-2019-127509

Published: 2019

Journal Articles

Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study

Blood (2019) 134 (Supplement_1): 468.

https://doi.org/10.1182/blood-2019-128513

Published: 2019

Journal Articles

A Single Dose of CD117 Antibody Drug Conjugate Enables Autologous Gene-Modified Hematopoietic Stem Cell Transplant (Gene Therapy) in Nonhuman Primates

Blood (2019) 134 (Supplement_1): 610.

https://doi.org/10.1182/blood-2019-125968

Published: 2019

Journal Articles

MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or "Add-on" to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis

John Mascarenhas, MD, Marina Kremyanskaya, Ronald Hoffman, MD, Prithviraj Bose, MD, Moshe Talpaz, MD, Claire N Harrison, Professor, Vikas Gupta, MD FRCP, FRCPath, Brian Leber, MD, Shireen Sirhan, MD, Sujan Kabir, MD, Adrian Senderowicz, MD, James Shao, MS, Jennifer Mertz, PhD, Patrick Trojer, PhD, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 670.

https://doi.org/10.1182/blood-2019-127119

Published: 2019

Journal Articles

Pharmacologic Activation of Aldehyde Metabolism to Protect Hematopoietic Stem Cells (HSC) in Murine Models of Fanconi Anemia (FA)

Jennifer Tsai, MD, Kelsey R. Logas, MS, Lauren D. Van Wassenhove, PhD, Beruh Dejene, BS, Che-Hong Chen, PhD, Daria Mochly-Rosen, PhD, Kenneth I. Weinberg, MD

Blood (2019) 134 (Supplement_1): 105.

https://doi.org/10.1182/blood-2019-124439

Published: 2019

Journal Articles

A Phase 1 Study of ACTR087 in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20-Positive B-Cell Lymphoma

Javier Munoz, MD, Samantha Jaglowski, MDMPH, Matthew S. McKinney, MD, Iris Isufi, MD, Patrick J. Stiff, MD, Jessica Sachs, MD, Ann Ranger, PhD, Patricia Harris, MPH, Francis Payumo, BSc, MSc, Luke P. Akard, MD

Blood (2019) 134 (Supplement_1): 244.

https://doi.org/10.1182/blood-2019-123810

Published: 2019

Journal Articles

Flowct: A Semi-Automated Workflow for Deconvolution of Immunophenotypic Data and Objective Reporting on Large Datasets

Blood (2019) 134 (Supplement_1): 4355.

https://doi.org/10.1182/blood-2019-122088

Published: 2019

Journal Articles

In Vivo Assessment of the Next Generation Microtubule-Destabilizing Agent AB8939 in Patient-Derived Xenograft Models of Acute Myeloid Leukemia

Armelle Goubard, PhD, Martine Humbert, PhD, Colin Mansfield, PhD, Olivier Hermine, MD PhD, Patrice Dubreuil, PhD, The AB8939 Study Group

Blood (2019) 134 (Supplement_1): 5142.

https://doi.org/10.1182/blood-2019-127143

Published: 2019

Journal Articles

Combination of Interferon α, Delivered By Engineered Mesenchymal Stromal Cells, and Cytarabine Limits the Development of Acute Myeloid Leukemia, Potentially Targeting Leukemic Stem Cells

Desbourdes M. Laura, PhD, Suheyla Hasgur, DVM, PhD, Adam J Guess, Minjun Yu, PhD, Satoru Otsuru, MD PhD, Edwin M. Horwitz, MD PhD

Blood (2019) 134 (Supplement_1): 5143.

https://doi.org/10.1182/blood-2019-127456

Published: 2019

Journal Articles

A Novel Revcar Platform for Switchable and Gated Tumor Targeting

Anja Feldmann, PhD, Anja Hoffmann, Enrico Kittel-Boselli, Ralf Bergmann, PhD, Stefanie Koristka, PhD, Nicole Berndt, PhD, Claudia Arndt, PhD, Liliana Raquel Loureiro, PhD, Nicola Mitwasi, Justyna Jureczek, Martin Bornhaeuser, MD, Michael Bachmann, MD

Blood (2019) 134 (Supplement_1): 5611.

https://doi.org/10.1182/blood-2019-128436

Published: 2019

Journal Articles

Development of Novel Anti-CD10 Target Modules for Redirection of Universal CAR T Cells Against CD10-Positive Malignancies

Anja Feldmann, PhD, Stefanie Koristka, PhD, Claudia Arndt, PhD, Liliana Raquel Loureiro, PhD, Ralf Bergmann, PhD, Nicole Berndt, PhD, Anja Hoffmann, Justyna Jureczek, Nicola Mitwasi, Martin Bornhaeuser, MD, Václav Hořejší, Michael Bachmann, MD

Blood (2019) 134 (Supplement_1): 5612.

https://doi.org/10.1182/blood-2019-128193

Published: 2019

Journal Articles

AB8939, a Microtubule-Destabilizing Agent with Potential to Overcome Multidrug Resistance, Is Active across the Range (M0-M7) of Acute Myeloid Leukemia Subtypes

Armelle Goubard, PhD, Martine Humbert, PhD, Colin Mansfield, PhD, Olivier Hermine, MD PhD, Patrice Dubreuil, PhD, The AB8939 Study Group

Blood (2019) 134 (Supplement_1): 5154.

https://doi.org/10.1182/blood-2019-127021

Published: 2019

Journal Articles

Highly Efficient Multiplexed Base Editing with Minimized Off-Targets for the Development of Universal CAR-T Cells to Treat Pediatric T-ALL

Jason M Gehrke, PhD, Aaron Edwards, MS, Ryan C. Murray, MS, Amy Shaw, MS, Yeh-Chuin Poh, PhD, Sarah Smith, Yi Yu, PhD, Nicole M. Gaudelli, PhD, Waseem Qasim, MBBS, PhD, Giuseppe Ciaramella, PhD, B.Sc.

Blood (2019) 134 (Supplement_1): 5127.

https://doi.org/10.1182/blood-2019-130562

Published: 2019

Journal Articles

High-Resolution Next-Generation Whole Genome Optical Mapping As a Novel Molecular Diagnostic Tool for Comprehensive Assessment of Structural Chromosomal Variations in Myelodysplastic Syndromes

Rashmi Kanagal-Shamanna, MD, Guillermo Montalban-Bravo, MD, Koji Sasaki, MD, Rajyalakshmi Luthra, PhD, Hui Yang, PhDMD, Gokce A. Toruner, MD PhD, Keyur P. Patel, MBBS, PhD, Saradhi Mallampati, DVM, PhD, Hagop M. Kantarjian, MD, Carlos E. Bueso-Ramos, MD PhD, L. Jeffrey Medeiros, MD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 5438.

https://doi.org/10.1182/blood-2019-131971

Published: 2019

Journal Articles

The Nutrient Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Feasibility Phase

Laura F. Mendez, Hellen Nguyen, Jenny Nguyen, Alexander Himstead, Melinda R. Lemm, Elena S. Heide, Robyn M. Scherber, MDMPH, Aditi Choudhry, MD, Chelsea O. McKinney, Ruben A. Mesa, MD, Lari Wenzel, Andrew Odegaard, Angela G. Fleischman, MD PhD

Blood (2019) 134 (Supplement_1): 5380.

https://doi.org/10.1182/blood-2019-130851

Published: 2019

Journal Articles

Nanoparticles Mimicking Platelets and Platelet Cloaking

Liangfang Zhang, PhD

Blood (2019) 134 (Supplement_1): SCI-38.

https://doi.org/10.1182/blood-2019-121082

Published: 2019

NARROW

Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML

Talazoparib Treatment Preferentially Depletes Cohesin-Mutant Clones in New In Vivo M odels of Cohesin-Mutant Myeloid Diseases

Integrated Immune Signature Analyses Identifies Evolution of Distinct Immunoregulatory Cell Populations Which Control Alloreactivity after Allogeneic HSCT

Pharmacological Inhibition of the RNA m 6 a Writer METTL3 As a Novel Therapeutic Strategy for Acute Myeloid Leukemia

Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor

Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study

A Single Dose of CD117 Antibody Drug Conjugate Enables Autologous Gene-Modified Hematopoietic Stem Cell Transplant (Gene Therapy) in Nonhuman Primates

MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or "Add-on" to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis

Pharmacologic Activation of Aldehyde Metabolism to Protect Hematopoietic Stem Cells (HSC) in Murine Models of Fanconi Anemia (FA)

A Phase 1 Study of ACTR087 in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20-Positive B-Cell Lymphoma

Flowct: A Semi-Automated Workflow for Deconvolution of Immunophenotypic Data and Objective Reporting on Large Datasets

In Vivo Assessment of the Next Generation Microtubule-Destabilizing Agent AB8939 in Patient-Derived Xenograft Models of Acute Myeloid Leukemia

Combination of Interferon α, Delivered By Engineered Mesenchymal Stromal Cells, and Cytarabine Limits the Development of Acute Myeloid Leukemia, Potentially Targeting Leukemic Stem Cells

A Novel Revcar Platform for Switchable and Gated Tumor Targeting

Development of Novel Anti-CD10 Target Modules for Redirection of Universal CAR T Cells Against CD10-Positive Malignancies

AB8939, a Microtubule-Destabilizing Agent with Potential to Overcome Multidrug Resistance, Is Active across the Range (M0-M7) of Acute Myeloid Leukemia Subtypes

Highly Efficient Multiplexed Base Editing with Minimized Off-Targets for the Development of Universal CAR-T Cells to Treat Pediatric T-ALL

High-Resolution Next-Generation Whole Genome Optical Mapping As a Novel Molecular Diagnostic Tool for Comprehensive Assessment of Structural Chromosomal Variations in Myelodysplastic Syndromes

The Nutrient Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Feasibility Phase

Nanoparticles Mimicking Platelets and Platelet Cloaking

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only